Stay updated on Cabozantinib in RAI-Refractory DTC Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib in RAI-Refractory DTC Clinical Trial page.

Latest updates to the Cabozantinib in RAI-Refractory DTC Clinical Trial page
- Check3 days agoChange DetectedThe page now displays Revision: v3.3.4 instead of v3.3.3. This is a metadata update with no visible changes to the study details or layout; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded a Locations section showing the Philadelphia, PA site (Abramson Cancer Center of the University of Pennsylvania) and updated the page revision to v3.3.3; removed the older Pennsylvania Locations entry and the HHS Vulnerability Disclosure link (v3.3.2).SummaryDifference0.3%

- Check53 days agoChange Detected- The page revision updated from v3.2.0 to v3.3.2. No study content or data appears to be changed.SummaryDifference0.1%

- Check60 days agoChange DetectedThe funding-status banner at the top of the page has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check74 days agoChange DetectedNo additions or deletions to core Study Details content were detected for NCT02041260. The page’s primary information, including eligibility criteria and trial details, remains unchanged.SummaryDifference0.5%

- Check103 days agoChange DetectedUpdate includes a critical operating-status notice and a new software version (v3.2.0) replacing the previous v3.1.0.SummaryDifference3%

Stay in the know with updates to Cabozantinib in RAI-Refractory DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib in RAI-Refractory DTC Clinical Trial page.